文献速递细菌感染、耐药与抗菌药物医院感染防控

不同全球区域患者碳青霉烯耐药肺炎克雷伯菌复合群的临床结局与细菌特征(CRACKLE-2):一项前瞻性多中心队列研究

Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study.
PubMed 文献 · Lancet Infect Dis · 2021-11-09

CRACKLE-2前瞻性多中心队列研究纳入8国71家医院991例碳青霉烯耐药肺炎克雷伯菌(CRKP)培养阳性住院患者,502例符合感染标准。感染者30天调整结局排名在中国、南美和美国间相似;南美调整30天全因死亡率高于中国(aOR 4.82)和美国(aOR 3.34),美国与中国间无显著差异(aOR 1.44)。

要点

  • CRKP感染者30天调整结局排名在中国、南美和美国间相似。
  • 南美调整30天全因死亡率高于中国(aOR 4.82)和美国(aOR 3.34)。
  • 美国与中国调整30天全因死亡率差异无统计学显著(aOR 1.44,95%CI 0.70-2.96)。

核心结论

  • 全球CRKP流行在患者基线特征、临床结局和细菌特征方面存在重要区域差异。
  • 来自一个区域的研究发现可能无法推广到其他区域。

研究设计与样本

  • 前瞻性、多中心、队列研究(CRACKLE-2),从阿根廷、澳大利亚、智利、中国、哥伦比亚、黎巴嫩、新加坡和美国的71家医院招募CRKP培养阳性住院患者。
  • 每例唯一患者纳入首次CRKP阳性培养,从健康记录收集出院后死亡和再入院临床数据,对所有分离株进行全基因组测序。
  • 主要结局为索引培养后30天结局期望排名,并与细菌特征和30天全因死亡率(关键次要结局)在中国、南美和美国患者间比较。
  • 结局期望排名通过逆概率加权调整入院前地点、Charlson合并症指数、培养时年龄、Pitt菌血症评分和解剖培养来源;死亡率通过多变量逻辑回归调整相同混杂因素(相关时加地区)。
  • 研究注册于ClinicalTrials.gov,NCT03646227,已完成。

主要发现

  • 2017年6月13日至2018年11月30日纳入991例患者,其中502例(51%)符合CRKP感染标准,489例(49%)培养阳性被认为定植。
  • CRKP国家内遗传变异小。
  • 美国感染患者比中国或南美患者病情更急(Pitt菌血症评分中位数3[IQR 2-6]vs 2[0-4]vs 2[0-4])且合并症更多(Charlson合并症指数中位数3[IQR 2-5]vs 1[0-3]vs 1[0-2])。
  • 中国(n=246)、南美(n=109)和美国(n=130)感染患者调整后结局期望排名相似,估计值中国vs南美53%(95%CI 42-65),美国vs中国50%(41-61),美国vs南美53%(41-66)。
  • CRKP感染患者未调整30天死亡率中国(12%,95%CI 8-16;246例中29例)低于美国(23%,16-30;130例中30例)和南美(28%,20-37;109例中31例);调整后30天全因死亡率南美高于中国(aOR 4.82,95%CI 2.22-10.50)和美国(aOR 3.34,1.50-7.47),美国与中国间差异不再显著(aOR 1.44,0.70-2.96)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a global threat. We therefore analysed the bacterial characteristics of CRKP infections and the clinical outcomes of patients with CRKP infections across different countries. METHODS: In this prospective, multicentre, cohort study (CRACKLE-2), hospitalised patients with cultures positive for CRKP were recruited from 71 hospitals in Argentina, Australia, Chile, China, Colombia, Lebanon, Singapore, and the USA. The first culture positive for CRKP was included for each unique patient. Clinical data on post-hospitalisation death and readmission were collected from health records, and whole genome sequencing was done on all isolates. The primary outcome was a desirability of outcome ranking at 30 days after the index culture, and, along with bacterial characteristics and 30-day all-cause mortality (a key secondary outcome), was compared between patients from China, South America, and the USA. The desirability of outcome ranking was adjusted for location before admission, Charlson comorbidity index, age at culture, Pitt bacteremia score, and anatomical culture source through inverse probability weighting; mortality was adjusted for the same confounders, plus region where relevant, through multivariable logistic regression. This study is registered at ClinicalTrials.gov, NCT03646227, and is complete. FINDINGS: Between June 13, 2017, and Nov 30, 2018, 991 patients were enrolled, of whom 502 (51%) met the criteria for CRKP infection and 489 (49%) had positive cultures that were considered colonisation. We observed little intra-country genetic variation in CRKP. Infected patients from the USA were more acutely ill than were patients from China or South America (median Pitt bacteremia score 3 [IQR 2-6] vs 2 [0-4] vs 2 [0-4]) and had more comorbidities (median Charlson comorbidity index 3 [IQR 2-5] vs 1 [0-3] vs 1 [0-2]). Adjusted desirability of outcome ranking outcomes were similar in infected patients from China (n=246), South America (n=109), and the USA (n=130); the estimates were 53% (95% CI 42-65) for China versus South America, 50% (41-61) for the USA versus China, and 53% (41-66) for the USA versus South America. In patients with CRKP infections, unadjusted 30-day mortality was lower in China (12%, 95% CI 8-16; 29 of 246) than in the USA (23%, 16-30; 30 of 130) and South America (28%, 20-37; 31 of 109). Adjusted 30-day all-cause mortality was higher in South America than in China (adjusted odds ratio [aOR] 4·82, 95% CI 2·22-10·50) and the USA (aOR 3·34, 1·50-7·47), with the mortality difference between the USA and China no longer being significant (aOR 1·44, 0·70-2·96). INTERPRETATION: Global CRKP epidemics have important regional differences in patients' baseline characteristics and clinical outcomes, and in bacterial characteristics. Research findings from one region might not be generalisable to other regions. FUNDING: The National Institutes of Health.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wang M, Earley M, Chen L, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect Dis. 2021. PMID: 34767753. doi:10.1016/S1473-3099(21)00399-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。